Reduced susceptibility to oxidation of low-density lipoprotein in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome)

Journal of Hypertension

Volumn 16, Issue 7, 1998, Pages 1001-1008

  Calò, Lorenzo ^a   Sartore, Giovanni ^a   Bassi, Andrea ^a   Basso, Cristina ^a   Bertocco, Sandra ^a   Marin, Raffaella ^a   Zambon, Sabina ^a   Cantaro, Salvatore ^a   D'Angelo, Angela ^a   Davis, Paul A ^b   Manzato, Enzo ^a   Crepaldi, Gaetano ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Bartter's syndrome; Gitelman's syndrome; Nitric oxide; Oxidation of low density lipoproteins

Indexed keywords

ALPHA TOCOPHEROL; COPPER SULFATE; FATTY ACID; LOW DENSITY LIPOPROTEIN; NITRATE; NITRIC OXIDE; NITRITE; POLYUNSATURATED FATTY ACID; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BARTTER SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; FEMALE; GAS CHROMATOGRAPHY; GITELMAN SYNDROME; HUMAN; LIPID COMPOSITION; LIPID OXIDATION; MALE; PARTICLE SIZE; PEROXIDATION; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 7344249538     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816070-00014     Document Type: Article

References (37)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-924.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809.
3. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man, J Clin Invest 1989; 84:1086-1095.
4. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012.
5. Cooke JP, Tsao PS. Is NO an antiatherogenic molecule? Arterioscler Thromb 1994; 14:653-655.
6. Jessup W, Mohr D, Gieseg SP, Dean RT, Stocker R. The participation of nitric oxide in cell free- and its restriction of macrophage-mediated oxidation of low-density lipoprotein. Biochim Biophys Acta 1992; 1180:73-82.
7. Yates MT, Lambert LE, Whitten JP, McDonald I, Mano M, Ku G, et al. A protective role for nitric oxide in the oxidative modification of low-density lipoproteins by mouse macrophages. FEBS Lett 1992; 309: 135-138
8. Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97:1989-1994.
9. Hogg A, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S. Inhibition of low density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 1993; 334:170-174
10. Jessup W, Dean RT. Autoinhibition of murine macrophage-mediated oxidation of low-density lipoprotein by nitric oxide synthesis. Atherosclerosis 1993; 101:145-155.
11. Clive DM. Bartter's syndrome: the unsolved puzzle. Am J Kidney Dis 1995; 25:813-823.
12. Bartter FC. Bartter's syndrome: a disorder of vascular reactivity. Hypertension 1981; 3:69-73.
13. Bettinelli A, Bianchetti MG, Girardin E, Caringella A, Cecconi M, Appiani AC, et al. Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: Bartter and Gitelman syndromes. J Pediatr 1992; 120:8-43.
14. Di Virgilio F, Calò L, Cantaro S, Favaro S, Piccoli A, Borsatti A. Resting and stimulated cytosolic free calcium levels in neutrophils from patients with Bartter's syndrome. Clin Sci 1987; 72:483-488.
15. Calò L, D'Angelo A, Cantaro S, Rizzolo M, Favaro S, Antonello A. Intracellular calcium signalling and vascular reactivity in Bartter's syndrome. Nephron 1996; 72:570-573.
16. Calò L, Cantaro S, Calabrò A, Piarulli F, Rizzolo M, Favaro S. Endothelium-derived vasoactive substances in Bartter's syndrome. Angiology 1995; 46:905-913.
17. 3 and cyclic guanosine monophosphate levels in patients with Bartter's syndrome: relationship to vascular reactivity. Am J Kidney Dis 1996; 27:784-789.
18. Calò L, Bordin MC, Davis PA, Cantaro S, Milani M, Gandolfi L, et al. Constitutive nitric oxide synthase gene expression in Bartter's and Gitelman's syndrome and its relationship to their vascular hyporesponsiveness. Contrib Nephrol 1997; 122:193-195.
19. Chung BH, Wilkinson T, Geer JC, Segrest JP. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res 1980; 21:284-291.
20. Chung BH, Segrest JP, Marjory JR, Brunzell JD, Hokanson JE, Krauss RM. Single vertical spin density gradient ultracentrifugation. In: Segrest JP, Albers JJ (editors): Methods in enzymology, plasma lipoproteins: preparation, structure and molecular biology, Orlando. Florida: Academic Press; 1986. Vol 128, pp. 181-209.
21. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense. low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94:350-356.
22. Esterbauer H, Striegl H, Puhl H, Rotheneder M, Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radical Res Commun 1989; 6:67-75.
23. Buege JA, Aust SD, Microsomal lipid peroxidation. In: Fleischer S, Packer L (editors): Methods in enzymology: biomembranes. Orlando, Florida: Academic Press; 1978. Vol 52, pp. 302-310.
24. Frankel EN, German JB, Davis PA. Headspace gas chromatography to determine human low density lipoprotein oxidation. Lipids 1992; 27:1047-1051.
25. Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226:497-509.
26. Egberts J, Bulskool R, Isolation of the acidic phospholipid phosphatidylglycerol from pulmonary surfactant by sorbent extraction chromatography. Clin Chem 1988; 34:163-164.
27. Morrison WR, Smith LM. Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol. J Lipid Res 1964; 5:600-608.
28. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20:470-475
29. Lipid Research Clinics Program. Lipid and lipoprotein analysis. In: Manual of laboratory operations. Second edition. Washington: USA Department of Health and Human Services; 1982. pp. 63-77
30. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28:2077-2080.
31. Ito Y, Ochiai J, Sasaki R, Suzuki S, Kusuhara Y, Morimitsu Y, Serum concentrations of carotenoids, retinol, and alpha-tocopherol in healthy persons determined by high-performance liquid chromatography. Clin Chim Acta 1990; 194:131-144.
32. Bruckdorfer KR, Jacobs M, Rice-Evans C. Endothelium-derived relaxing factor (nitric oxide), lipoprotein oxidation and atherosclerosis. Biochem Soc Trans 1990; 18:1061-1063.
33. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43:109-142.
34. Anderson TJ, Meredith IT, Charbonneau F, Yeung AC, Frei B, Selwyn AP, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996; 93:1647-1650.
35. Tribble DL. Lipoprotein oxidation in dyslipidemia: insights into general mechanisms affecting lipoprotein oxidative behavior. Curr Opin Lipidol 1995; 6:196-208.
36. Lambert J, Aarsen M, Donker AJM, Stehouwer CDA. Endothelium-dependent and independent vasodilation in large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16:705-711.
37. Witteman JMC, Grobbee DE, Valkenburg HA, van Hemert AM, Stijnen T, Hofman A, Cigarette smoking and the development and progression of aortic atherosclerosis: a 9-year population-based follow-up study in women. Circulation 1993; 88:2156-2162.